Cited by 937Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal Development and Disorders

Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease

Open access
Mullins, Robert F., Russell, Stephen R., Anderson, Don H., Hageman, Gregory S.·2000·The FASEB Journal

Abstract

Age‐related macular degeneration (AMD), a blinding disorder that compromises central vision, is characterized by the accumulation of extracellular deposits, termed drusen, between the retinal pigmented epithelium and the choroid. Recent studies in this laboratory revealed that vitronectin is a major component of drusen. Because vitronectin is also a constituent of abnormal deposits associated with a variety of diseases, drusen from human donor eyes were examined for compositional similarities with other extracellular disease deposits. Thirty‐four antibodies to 29 different proteins or protein complexes were tested for immunoreactivity with hard and soft drusen phenotypes. These analyses provide a partial profile of the molecular composition of drusen. Serum amyloid P component, apolipoprotein E, immunoglobulin light chains, Factor X, and complement proteins (C5 and C5b‐9 complex) were identified in all drusen phenotypes. Transcripts encoding some of these molecules were also found to be synthesized by the retina, retinal pigmented epithelium, and/or choroid. The compositional similarity between drusen and other disease deposits may be significant in view of the recently established correlation between AMD and atherosclerosis. This study suggests that similar pathways may be involved in the etiologies of AMD and other age‐related diseases.—Mullins, R. F., Russell, S. R., Anderson, D. H., Hageman, G. S. Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835–846 (2000)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1096/fasebj.14.7.835

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Apolipoproteins B and E, immunoglobulins, factor X, amyloid P component, amyloid β, complement C5 and C5b-9 terminal complexes, fibrinogen, and vitronectin are present in all phenotypes of hard and soft drusen.

    “Immunohistochemical analyses have shown various molecular constituents, such as apolipoproteins B and E, different immunoglobulins, factor X, amyloid P component, amyloid β, complement C5 and C5b-9 terminal complexes, fibrinogen, vitronectin, and others, to be present in all phenotypes of hard and soft drusen”

    From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Mullins et al., 2000

  • Carboxyethyl pyrrole immunoreactive proteins in AMD Bruch's membrane include albumin and alpha-1-antitrypsin.

    “Among the nine identified immunopositive proteins were albumin and 𝛂 1-antitrypsin, both of which were detected in drusen by LC MS ∕ MS (Table 3) and immunocytochemistry (14).”
  • Biochemical analysis of drusen has identified glycoconjugates and components found in atherosclerotic plaques, including vitronectin, apolipoprotein B and E, alpha-crystallin, complement proteins, and lipids.

    “Biochemical analysis of drusen has identified glycoconjugates and components found in atherosclerotic plaques including vitronectin, apolipoprotein B and E, alpha-crystallin, complement proteins, and lipids (32, 106, 115).”
  • Drusen contain acute phase proteins, complement pathway components and inhibitors, apolipoproteins B and E, mucopolysaccarides, lipids, mannose, and sialic acid.

    “Studies analyzing the composition of drusen have shown that drusen contain acute phase proteins (C-reactive protein, vitronectin, α-antichymotrypsin, amyloid P component, and fibrinogen), complement pathway components (C3, C5 and C5b-9 complex) and inhibitors (clusterin), apolipoproteins B and E, mucopolysaccarides, lipids, mannose, and sialic acid (Farkas et al., 1971; Mullins et al., 2000).”
  • cfh−/− mice have C3 accumulation in the retina, secondary C3 deficiency, and uncontrolled C3 activation.

    “The cfh−/− mice had C3 accumulation in the retina, secondary C3 deficiency, and uncontrolled C3 activation, which may increase phagocytic uptake and cause neural damage to the retina (Mullins et al., 2000; Coffey et al., 2007).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Oppenheim, J., and Leonard, E. (1989) Introduction to hu- man monocytes. In Human Monocytes (Zembala, M., and Ash- erson, G., eds) Academic Press, San Diego, California
  2. Sarks, S., and Sarks, J. (1989) Age-related macular degenera- tion: atrophic form. In The Retina (Ryan, S., ed) Vol. 2, CV Mosby, St. Louis, Missouri

Cited by

Sorted by citations

Authors
Mullins, R. F., Russell, S. R., Anderson, D. H., & Hageman, G. S.
Affiliations
  • University of Iowa (US)
  • University of California, Santa Barbara (US)
Corresponding author
Hageman, Gregory S.
Venue
The FASEB Journal
Publisher
Wiley
Published
2000-05
Volume
14
Issue
7
Pages
835-846
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W1883306593
Cited by
937
References
110
Citations by year
2026: 14 · 2025: 24 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 40 · 2020: 41 · 2019: 23 · 2018: 33 · 2017: 44 · 2016: 35 · 2015: 44 · 2014: 48 · 2013: 59 · 2012: 42
FWCI
25.81
Type
journal article
Language
en
Open access
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
NIH Office of the Director (EY06463, EY11515, EY11521, AG00214)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
Keywords
drusen, age-related macular degeneration, vitronectin, atherosclerosis, elastosis, amyloidosis, dense deposit disease, serum amyloid P component, apolipoprotein E, immunoglobulin light chains, factor X, complement C5, complement C5b-9, retinal pigment epithelium, choroid, aging, protein composition
MeSH terms
Aging, Amyloidosis, Arteriosclerosis, Base Sequence, Humans, Immunohistochemistry, Macular Degeneration, Proteins, RNA, Messenger, Skin Diseases, Glomerulonephritis, Membranoproliferative, Retinal Drusen, DNA Primers, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review